Results 1 to 10 of about 16,042 (257)

Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022 [PDF]

Emerging Infectious Diseases
Given its enhanced genetic stability, novel oral poliovirus vaccine type 2 was deployed for type 2 poliovirus outbreak responses under World Health Organization Emergency Use Listing. We evaluated the safety profile of this vaccine.
Farrell A. Tobolowsky, Fred Nsubuga, Zunera Gilani, Annet Kisakye, Helen Ndagije, Daniel Kyabayinze, Jane F. Gidudu   +6 more
doaj   +4 more sources

Immunogenicity and safety evaluation of bivalent types 1 and 3 oral poliovirus vaccine by comparing different poliomyelitis vaccination schedules in China: A randomized controlled non-inferiority clinical trial [PDF]

Human Vaccines & Immunotherapeutics, 2017
Background: The type 2 component of the oral poliovirus vaccine is targeted for global withdrawal through a switch from the trivalent oral poliovirus vaccine (tOPV) to a bivalent oral poliovirus vaccine (bOPV). The switch is intended to prevent paralytic
Jingjun Qiu, Yunkai Yang, Lirong Huang, Ling Wang, Zhiwei Jiang, Jian Gong, Wei Wang, Hongyan Wang, Shaohong Guo, Chanjuan Li, Shuyuan Wei, Zhaojun Mo, Jielai Xia   +12 more
doaj   +2 more sources

Emergence of vaccine-derived poliovirus type 2 after using monovalent type 2 oral poliovirus vaccine in an outbreak response, Philippines [PDF]

Western Pacific Surveillance and Response, 2022
Objective: In response to an outbreak of circulating vaccine-derived poliovirus (cVDPV) type 2 in the Philippines in 2019–2020, several rounds of supplementary immunization activities using the monovalent type 2 oral poliovirus vaccine (OPV) were ...
SweetC B Alipon, Yoshihiro Takashima, Tigran Avagyan, Varja Grabovac, Syeda Kanwal Aslam, Benjamin Bayutas, Josephine Logronio, Xiaojun Wang, Achyut Shrestha, Sukadeo Neupane, Maria Concepcion Roces, Lea Necitas Apostol, Nemia Sucaldito   +12 more
doaj   +2 more sources

Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry [PDF]

Frontiers in Immunology, 2017
Individuals with primary immunodeficiency disorder may excrete poliovirus for extended periods and will constitute the only remaining reservoir of virus after eradication and withdrawal of oral poliovirus vaccine.
Grace Macklin, Yi Liao, Yi Liao, Marina Takane, Kathleen Dooling, Stuart Gilmour, Ondrej Mach, Olen M. Kew, Olen M. Kew, Roland W. Sutter, The iVDPV Working Group, Ousmane Diop, Nicksy Gumede Moeletsi, Raffaella Williams, Mohamed Seghier, Francis Delpeyroux, Gloria Rey Benito, Maria Cecilia Freire, Cara Burns, Humayun Asghar, Salman Sharif, Jagadish Deshpande, Shohreh Shahmahmoodi, Henda Triki, Laila E Bassioni, Amina Al-Jardani, Eugene Merav Weil Gavrilin, Javier Martín, Sirima Pattamadilok, Sunethra Gunasena, Yan Zhang, Wenbo Xu   +31 more
doaj   +4 more sources

Poliovirus shedding after sequential immunization of Sabin-strain inactivated polio vaccines and oral attenuated polio vaccines [PDF]

npj Vaccines
The identification of poliovirus in stool samples post-Oral Poliovirus Vaccine (OPV) immunization is essential for implementing post-eradication monitoring of poliomyelitis.
Yuting Fu, Rufei Ma, Zhimei Zhao, Zhaojun Mo, Zhifang Ying, Jing Li, Hui Ye, Guoliang Li, Xiaochang Liu, Jiangli Liang, Ling Ping, Jingyan Li, Junhui Tao, Qinghai Yang, Dingkai Wei, Li Yi, Hongbo Chen, Jianfeng Wang, Ruiju Jiang, Lei Yu, Wei Cai, Wei Yang, Lei Yue, Mingxue Xie, Qiongzhou Yin, Jing Pu, Chao Hong, Lukui Cai, Yan Deng, Jiana Wen, Yan Ma, Na Gao, Xiaoyu Wang, Hongwei Liao, Qiuyan Ji, Guang Ji, Wenzhu Hu, Qin Gu, Xiaoyue He, Han Chu, Yixian Fu, Jian Zhou, Yu Wen, Xiaolei Yang, Changgui Li, Li Shi, Ting Zhao, Teng Huang, Jingsi Yang   +48 more
doaj   +2 more sources

Rapid emergence and transmission of virulence-associated mutations in the oral poliovirus vaccine following vaccination campaigns. [PDF]

NPJ Vaccines, 2023
Walter KS, Altamirano J, Huang C, Carrington YJ, Zhou F, Andrews JR, Maldonado Y.   +6 more
europepmc   +3 more sources

Notes from the Field: Circulating Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use - Six African Countries, 2021-2023. [PDF]

MMWR Morb Mortal Wkly Rep, 2023
Davlantes E, Jorba J, Henderson E, Bullard K, Deka MA, Kfutwah A, Martin J, Bessaud M, Shulman LM, Hawes K, Diop OM, Bandyopadhyay AS, Zipursky S, Burns CC.   +13 more
europepmc   +3 more sources

Safety and immunogenicity of shorter interval schedules of the novel oral poliovirus vaccine type 2 in infants: a phase 3, randomised, controlled, non-inferiority study in the Dominican Republic. [PDF]

Lancet Infect Dis, 2023
Rivera Mejía L, Peña Méndez L, Bandyopadhyay AS, Gast C, Mazara S, Rodriguez K, Rosario N, Zhang Y, Mainou BA, Jimeno J, Aguirre G, Rüttimann R.   +11 more
europepmc   +2 more sources

Safety and immunogenicity of two novel type 2 oral poliovirus vaccine candidates compared with a monovalent type 2 oral poliovirus vaccine in healthy adults: two clinical trials. [PDF]

Lancet, 2021
De Coster I, Leroux-Roels I, Bandyopadhyay AS, Gast C, Withanage K, Steenackers K, De Smedt P, Aerssens A, Leroux-Roels G, Oberste MS, Konopka-Anstadt JL, Weldon WC, Fix A, Konz J, Wahid R, Modlin J, Clemens R, Costa Clemens SA, Bachtiar NS, Van Damme P.   +19 more
europepmc   +2 more sources

Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences. [PDF]

Risk Anal, 2023
Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM.   +6 more
europepmc   +3 more sources